Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
Home
› Best Practices
Viral Safety Evaluation
- Date: February 18, 2011
- Source: Admin
Standards in controlling viral contamination of biotechnology products:
- Selection and testing of starting materials (cell banks, raw materials etc.)
- Product testing at various stages of production
- Assessing the capacity of the production processes to clear infectious viruses and incorporating viral inactivation and removal steps.
Strategies to evaluate risk of viral contamination and removal of virus:
- Thorough characterization/screening of cell substrate starting material in order to identify which, if any, viral contaminants are present
- Assessment of risk by determination of the human tropism of the contaminants
- Establishment of an appropriate program of testing for adventitious viruses in unprocessed bulk
- Careful design of viral clearance studies using different methods of virus inactivation or removal in the same production process in order to achieve maximum viral clearance
- Performance of studies which assess virus inactivation and removal
Virus Safety Principles
ICH: Q5A or CPMP/ICH/295/95: Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
- Cell line qualification: testing of viruses
- Testing for viruses in unprocessed bulk
- Evaluation and characterization of viral clearance studies
Regulatory guidelines
ICH Q5A: 1. Viral Safety Evaluation of Biotechnology Products Derived from Cell lines of Human or Animal origin 1, (1997) |
· Requires manufacturer to demonstrate the capability of the manufacturing process to remove or inactivate known contaminants. |
FDA: 1. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use 2 (1997) 2. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals 3 (1993) |
· Similar guidelines as ICH Q5A guideline
· Further viral safety evaluation methods |
EMEA - CPMP guidelines: The 2008 EMEA – CHMP guidelines on viral validation 1. Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products 4 1996 EMEA - CPMP guidelines 2. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses 5 3. CPMP’s Note for Guidance on Plasma Derived Medicinal Products 6 provides detailed recommendations for the manufacturers of biopharmaceutical products to follow when performing viral validations. |
· Recommendations for manufacturers to follow when performing viral validations · Set specific values for virus clearance levels that had to be attained
|
EU Clinical Trials Directive 2001/20/EC 7
The International Standard ISO 22442-3: Medical devices utilizing animal tissues and their derivatives – Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents 8 |
· All EU Member States now require submission of an Investigational Medicinal Product Dossier (IMPD) starting at phase 1
· Requirements on viral clearance for the medical devices
|
Guidance
FDA Q5A Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin |
Describes approaches risk evaluation of viral contamination and potential of the production process to remove viruses. |
Source
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073454.pdf
http://www.microbac.com/technical_articles/news_detail.php?news_ID=64
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129101.pdf
Compliance Trainings
Pregnancy in the Workplace: Strategies to Protect Your Organization from Pregnancy Discrimination Claims
By - Christopher W. Olmsted
On Demand Access Anytime
By - Christopher W. Olmsted
On Demand Access Anytime
How to Vet an IRB: Expose and Fix Problems Before They Threaten Your Trial
By - Madhavi Diwanji
On Demand Access Anytime
By - Madhavi Diwanji
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed